CLOuD is a multicentre, randomised trial of an exciting new artificial pancreas device, in newly diagnosed adolescents with type 1 diabetes (T1D). It is designed to mimic the normal activity of beta-islet pancreatic cells in response to blood glucose levels. The device is a closed loop system combining real-time continuous glucose monitoring with insulin pump therapy and a computer-based algorithm to calculate the amount of insulin required to keep blood glucose levels within target range. The aim is to prolong residual insulin secretion after T1D diagnosis, via intensive metabolic control using the artificial pancreas closed loop system, in order to minimise long-term complications and reduce the risk of hypoglycaemia. 96 newly diagnosed subjects with T1D will be randomised 1:1 to either closed loop or standard therapy (multiple daily injections). Participants will have study visits and assessments every 3 months for a total of 24 months.